Alemtuzumab (anti-CD52 monoclonal antibody) as single-agent therapy in patients with relapsed/refractory chronic lymphocytic leukaemia (CLL)—a single region experience on consecutive patients
Crossref DOI link: https://doi.org/10.1007/s00277-014-2105-1
Published Online: 2014-05-21
Published Print: 2014-10
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Eketorp Sylvan, S.
Lundin, J.
Ipek, M.
Palma, M.
Karlsson, C.
Hansson, L.
Text and Data Mining valid from 2014-05-21